Definium Therapeutics (DFTX) Cash from Operations (2019 - 2026)

Definium Therapeutics (DFTX) has 7 years of Cash from Operations data on file, last reported at 42631000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 42631000.0, down 44.91% year-over-year; the trailing twelve-month figure through Mar 2026 was 144772000.0 (down 57.45% YoY), and the FY2025 annual result was 131560000.0, down 66.26% from the prior year.
• Cash from Operations improved to 42631000.0 in Q1 2026 per DFTX's latest filing, from 42975000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 9297000.0 in Q3 2022 and troughed at 42975000.0 in Q4 2025.
• A 5-year average of 21636705.88 and a median of 17191000.0 in 2024 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations surged 44.6% in 2022, then sank 78.83% in 2023.
• A 5-year view of Cash from Operations shows it stood at 12849000.0 in 2022, then sank by 60.04% to 20563000.0 in 2023, then retreated by 23.28% to 25351000.0 in 2024, then sank by 69.52% to 42975000.0 in 2025, then grew by 0.8% to 42631000.0 in 2026.
• Business Quant data shows DFTX's Cash from Operations at 42631000.0 in Q1 2026, 42975000.0 in Q4 2025, and 29567000.0 in Q3 2025.